Cogent Biosciences (COGT) Non-Current Assets (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Non-Current Assets of $25.2 million for Q1 2026, down 18.47% year-over-year from $30.9 million in Q1 2025, and down 7.52% quarter-over-quarter from $27.3 million in Q4 2025.
Cogent Biosciences (COGT) Non-Current Assets (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Non-Current Assets for 10 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 18.47% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $111.0 million (down 32.67% YoY), while the FY2025 annual figure was $27.3 million, down 13.28% from the prior year.
- Non-Current Assets eased to $25.2 million in Q1 2026 per COGT's latest filing, from $27.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $69.5 million in Q3 2023 and bottomed at $12.1 million in Q1 2022.
- Historically, Non-Current Assets has averaged $37.4 million across 5 years, with a median of $35.1 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 393.68% — and 2025, when it tumbled 50.29%.
- Cogent Biosciences' Non-Current Assets stood at $35.8 million in 2022, then advanced by 19.03% to $42.7 million in 2023, then slipped by 26.34% to $31.4 million in 2024, then retreated by 13.28% to $27.3 million in 2025, then decreased by 7.52% to $25.2 million in 2026.
- Business Quant data shows COGT's Non-Current Assets at $25.2 million in Q1 2026, $27.3 million in Q4 2025, and $28.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 29.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.73 Mn |
| Mar 31, 2026 | 25.20 Mn |
| Dec 31, 2025 | 27.25 Mn |
| Sep 30, 2025 | 28.69 Mn |
| Jun 30, 2025 | 29.81 Mn |
| Mar 31, 2025 | 30.91 Mn |
| Dec 31, 2024 | 31.43 Mn |
| Sep 30, 2024 | 42.49 Mn |
| Jun 30, 2024 | 59.96 Mn |
| Mar 31, 2024 | 34.21 Mn |
| Dec 31, 2023 | 42.67 Mn |
| Sep 30, 2023 | 69.49 Mn |
| Jun 30, 2023 | 57.85 Mn |
| Mar 31, 2023 | 36.93 Mn |
| Dec 31, 2022 | 35.84 Mn |
| Sep 30, 2022 | 35.14 Mn |
| Jun 30, 2022 | 35.38 Mn |
| Mar 31, 2022 | 12.14 Mn |
| Dec 31, 2021 | 9.46 Mn |
| Sep 30, 2021 | 7.88 Mn |